Hansa Biopharma announces study design for a US randomized, controlled trial of imlifidase in highly sensitized kidney transplant patients
First patient expected to be included in second half of 2021 with results expected to support a submission of a Biologics License Application (BLA) under the accelerated approval pathway in the first half of 2024.Lund, Sweden June 23, 2021 Hansa Biopharma AB “Hansa”, (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces the study design for a randomized, controlled clinical trial to investigate imlifidase as a potential desensitization therapy to enable kidney transplants in highly sensitized patients waiting for a compatible deceased